Caged-carvedilol as a new tool for visible-light photopharmacology of β-adrenoceptors in native tissues

Biochemistry; Cell biology; PharmacologyBioquímica; Biologia cel·lular; FarmacologiaBioquímica; Biología celular; FarmacologíaAdrenoceptors are G protein-coupled receptors involved in a large variety of physiological processes, also under pathological conditions. This is due in large part to their ubiquitous expression in the body exerting numerous essential functions. Therefore, the possibility to control their activity with high spatial and temporal precision would constitute a valuable research tool. In this study, we present a caged version of the approved non-selective β-adrenoceptor antagonist carvedilol, synthesized by alkylation of its secondary amine with a coumarin derivative. Introducing this photo-removable group abolished carvedilol physiological effects in cell cultures, mouse isolated perfused hearts and living zebrafish larvae. Only after visible light application, carvedilol was released and the different physiological systems were pharmacologically modulated in a similar manner as the control drug. This research provides a new photopharmacological tool for a wide range of research applications that may help in the development of future precise therapies.This work was supported by ERDF-FEDER European Fund (projects CTQ2017-89222-R) and by the Catalan government (2017SGR 1604) to AL. Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (PID2020-120499RB-I00) supported XR and AL. XR research was financed by the Spanish Ministry of Economy, Industry and Competitiveness (SAF2015-74132-JIN). MF was supported by the “Agencia Estatal deInvestigación” from the Spanish Ministry of Science and Innovation and the IDAEA-CSIC, a Centre of Excellence Severo Ochoa (CEX2018-000794-S). ARS has a consolidated Miguel Servet contract and was financed by by the Catalan government (2017-SGR-1807). ADC received the support of a fellowship from “la Caixa” Foundation (ID 100010434) under the fellowship codeLCF/BQ/DE18/11670012

Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis

Diabetes mellitus entails increased atherosclerotic burden and medial arterial calcification, but the precise mechanisms are not fully elucidated. We aimed to investigate the implication of CD36 in inflammation and calcification processes orchestrated by vascular smooth muscle cells (VSMCs) under hyperglycemic and atherogenic conditions. We examined the expression of CD36, pro-inflammatory cytokines, endoplasmic reticulum (ER) stress markers, and mineralization-regulating enzymes by RT-PCR in human VSMCs, cultured in a medium containing normal (5 mM) or high glucose (22 mM) for 72 h with or without oxidized low-density lipoprotein (oxLDL) (24 h). The uptake of 1,1'-dioctadecyl-3,3,3',3-tetramethylindocarbocyanine perchlorate-fluorescently (DiI) labeled oxLDL was quantified by flow cytometry and fluorimetry and calcification assays were performed in VSMC cultured in osteogenic medium and stained by alizarin red. We observed induction in the expression of CD36, cytokines, calcification markers, and ER stress markers under high glucose that was exacerbated by oxLDL. These results were confirmed in carotid plaques from subjects with diabetes versus non-diabetic subjects. Accordingly, the uptake of DiI-labeled oxLDL was increased after exposure to high glucose. The silencing of CD36 reduced the induction of CD36 and the expression of calcification enzymes and mineralization of VSMC. Our results indicate that CD36 signaling is partially involved in hyperglycemia and oxLDL-induced vascular calcification in diabetes

Hipertrofia cardiomiocitária induzida por angiotensina II: Uma resposta complexa dependente de vias entrelaçadas

Hipertrofia cardiomiocitáriaHipertròfia cardiomiocitàriaCardiomyocyte hypertrophyThis study was supported by the Spanish Ministry of Economy and Competitiveness and Instituto de Salud Carlos III (PI17/01397 and CIBERCV), and cofinanced by the European Regional Development Fund (ERDF, ‘a Way to Build Europe’). Antonio Rodríguez-Sinovas has a consolidated Miguel Servet contract